


SARS-CoV-2-IN-25

Cat. No.:	HY-151267
Molecular Formula:	C ₅₈ H ₄₈ O ₈ P ₂
Molecular Weight:	934.94
Target:	SARS-CoV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	SARS-CoV-2-IN-25 (Compound CP026) is a potent SARS-CoV-2 spike pseudoparticle transduction inhibitor with an IC ₅₀ of 1.6 μM. SARS-CoV-2-IN-25 inhibits enveloped viruses and liposomes ^[1] .
IC₅₀ & Target	IC ₅₀ : 1.5 μM (HIV-1), 1.6 μM (SARS-CoV-2 spike pseudoparticle transduction), 1.8 μM (SARS-CoV-2), 1.9 μM (MeV), 11.6 μM (IAV) ^[1] EC ₅₀ : 2.6 μM (liposome) ^[1]
In Vitro	SARS-CoV-2-IN-25 (Compound CP026) shows cytotoxicity with a CC ₅₀ of 117.9 μM against Caco2 cells ^[1] . SARS-CoV-2-IN-25 inhibits SARS-CoV-2, IAV, MeV, HIV-1 with IC ₅₀ s of 1.8, 11.6, 1.9 and 1.5 μM, respectively. SARS-CoV-2-IN-25 inhibits liposome with an EC ₅₀ of 2.6 μM ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Weil T, et al. Advanced Molecular Tweezers with Lipid Anchors against SARS-CoV-2 and Other Respiratory Viruses. JACS Au, 2022.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA